Structural Insights into the Mechanisms of Antibody-Mediated Neutralization of Flavivirus Infection: Implications for Vaccine Development

Cell Host and Microbe

Volumn 4, Issue 3, 2008, Pages 229-238

  Pierson, Theodore C ^a   Fremont, Daved H ^b   Kuhn, Richard J ^c   Diamond, Michael S ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C4B; FC RECEPTOR; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN; VIRUS VACCINE;

ANTIGEN STRUCTURE; COMPLEMENT ACTIVATION; DISEASE SEVERITY; DRUG RESEARCH; DRUG TARGETING; FLAVIVIRUS; HUMAN; HUMORAL IMMUNITY; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNA VIRUS; STOICHIOMETRY; VIRION; VIRUS INFECTION; VIRUS MORPHOLOGY; VIRUS NEUTRALIZATION; VIRUS RESISTANCE;

ANTIBODIES, VIRAL; ANTIGENS, VIRAL; COMPLEMENT ACTIVATION; FLAVIVIRUS; FLAVIVIRUS INFECTIONS; HUMANS; MODELS, IMMUNOLOGICAL; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

FLAVIVIRUS; RNA VIRUSES;

EID: 50849120046     PISSN: 19313128     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chom.2008.08.004     Document Type: Review

References (80)

1. Anderson R. Manipulation of cell surface macromolecules by flaviviruses. Adv. Virus Res. 59 (2003) 229-274
2. Arjona A., Ledizet M., Anthony K., Bonafe N., Modis Y., Town T., and Fikrig E. West Nile virus envelope protein inhibits dsRNA-induced innate immune responses. J. Immunol. 179 (2007) 8403-8409
3. Blaney Jr. J.E., Matro J.M., Murphy B.R., and Whitehead S.S. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys. J. Virol. 79 (2005) 5516-5528
4. Burnet F.M., Keogh E.V., and Lush D. The immunological reactions of the filterable viruses. Aust. J. Exp. Biol. Med. Sci. 15 (1937) 227-368
5. Burton D.R., Saphire E.O., and Parren P.W. A model for neutralization of viruses based on antibody coating of the virion surface. Curr. Top. Microbiol. Immunol. 260 (2001) 109-143
6. Cardosa M.J., Porterfield J.S., and Gordon S. Complement receptor mediates enhanced flavivirus replication in macrophages. J. Exp. Med. 158 (1983) 258-263
7. Carroll M.C. The complement system in regulation of adaptive immunity. Nat. Immunol. 5 (2004) 981-986
8. Chambers T.J., Droll D.A., Walton A.H., Schwartz J., Wold W.S., and Nickells J. West Nile 25A virus infection of B-cell-deficient (μMT) mice: characterization of neuroinvasiveness and pseudoreversion of the viral envelope protein. J. Gen. Virol. 89 (2008) 627-635
9. Chau T.N., Quyen N.T., Thuy T.T., Tuan N.M., Hoang D.M., Dung N.T., Lien L.B., Quy N.T., Hieu N.T., Hieu L.T., et al. Dengue in Vietnamese infants--results of infection-enhancement assays correlate with age-related disease epidemiology, and cellular immune responses correlate with disease severity. J. Infect. Dis. 198 (2008) 516-524
10. Chiou S.S., Crill W.D., Chen L.K., and Chang G.J. Enzyme-linked immunosorbent assays using novel Japanese encephalitis virus antigen improve the accuracy of clinical diagnosis of flavivirus infections. Clin Vaccine Immunol. 15 (2008) 825-835
11. Crill W.D., and Roehrig J.T. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J. Virol. 75 (2001) 7769-7773
12. Crill W.D., and Chang G.J. Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J. Virol. 78 (2004) 13975-13986
13. Davis C.W., Nguyen H.Y., Hanna S.L., Sanchez M.D., Doms R.W., and Pierson T.C. West Nile virus discriminates between DC-SIGN and DC-SIGNR for cellular attachment and infection. J. Virol. 80 (2006) 1290-1301
14. Della-Porta A.J., and Westaway E.G. A multi-hit model for the neutralization of animal viruses. J. Gen. Virol. 38 (1978) 1-19
15. Despres P., Combredet C., Frenkiel M.P., Lorin C., Brahic M., and Tangy F. Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis. J. Infect. Dis. 191 (2005) 207-214
16. Diamond M.S., Shrestha B., Marri A., Mahan D., and Engle M. B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J. Virol. 77 (2003) 2578-2586
17. Dulbecco R., Vogt M., and Strickland A.G. A study of the basic aspects of neutralization of two animal viruses, western equine encephalitis virus and poliomyelitis virus. Virology 2 (1956) 162-205
18. Gollins S.W., and Porterfield J.S. Flavivirus infection enhancement in macrophages: radioactive and biological studies on the effect of antibody on viral fate. J. Gen. Virol. 65 (1984) 1261-1272
19. Gollins S.W., and Porterfield J.S. A new mechanism for the neutralization of enveloped viruses by antiviral antibody. Nature 321 (1986) 244-246
20. Goncalvez A.P., Chien C.H., Tubthong K., Gorshkova I., Roll C., Donau O., Schuck P., Yoksan S., Wang S.D., Purcell R.H., et al. Humanized monoclonal antibodies derived from chimpanzee Fabs protect against Japanese encephalitis virus in vitro and in vivo. J. Virol. 82 (2008) 7009-7021
21. Goncalvez A.P., Purcell R.H., and Lai C.J. Epitope determinants of a chimpanzee Fab antibody that efficiently cross-neutralizes dengue type 1 and type 2 viruses map to inside and in close proximity to fusion loop of the dengue type 2 virus envelope glycoprotein. J. Virol. 78 (2004) 12919-12928
22. Gould L.H., Sui J., Foellmer H., Oliphant T., Wang T., Ledizet M., Murakami A., Noonan K., Lambeth C., Kar K., et al. Protective and therapeutic capacity of human single chain Fv-Fc fusion proteins against West Nile virus. J. Virol. 79 (2005) 14606-14613
23. Green S., and Rothman A. Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Curr. Opin. Infect. Dis. 19 (2006) 429-436
24. Gromowski G.D., and Barrett A.D. Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology 366 (2007) 349-360
25. Gromowski G.D., Barrett N.D., and Barrett A.D. Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. J. Virol. 82 (2008) 8828-8837
26. Gubler D.J. Dengue and dengue hemorrhagic fever. Clin. Microbiol. Rev. 11 (1998) 480-496
27. Guirakhoo F., Heinz F.X., Mandl C.W., Holzmann H., and Kunz C. Fusion activity of flaviviruses: comparison of mature and immature (prM-containing) tick-borne encephalitis virions. J. Gen. Virol. 72 (1991) 1323-1329
28. Guirakhoo F., Bolin R.A., and Roehrig J.T. The Murray Valley encephalitis virus prM protein confers acid resistance to virus particles and alters the expression of epitopes within the R2 domain of E glycoprotein. Virology 191 (1992) 921-931
29. Halevy M., Akov Y., Ben-Nathan D., Kobiler D., Lachmi B., and Lustig S. Loss of active neuroinvasiveness in attenuated strains of West Nile virus: pathogenicity in immunocompetent and SCID mice. Arch. Virol. 137 (1994) 355-370
30. Halstead S.B. Neutralization and antibody-dependent enhancement of dengue viruses. Adv. Virus Res. 60 (2003) 421-467
31. Halstead S.B., and O'Rourke E.J. Antibody-enhanced dengue virus infection in primate leukocytes. Nature 265 (1977) 739-741
32. He R.T., Innis B.L., Nisalak A., Usawattanakul W., Wang S., Kalayanarooj S., and Anderson R. Antibodies that block virus attachment to Vero cells are a major component of the human neutralizing antibody response against dengue virus type 2. J. Med. Virol. 45 (1995) 451-461
33. Heinz F.X., and Kunz C. Tick-borne encephalitis and the impact of vaccination. Arch. Virol. Suppl. (2004) 201-205
34. Heinz F.X., Stiasny K., Puschner-Auer G., Holzmann H., Allison S.L., Mandl C.W., and Kunz C. Structural changes and functional control of the tick-borne encephalitis virus glycoprotein E by the heterodimeric association with protein prM. Virology 198 (1994) 109-117
35. Hennessy S., Liu Z., Tsai T.F., Strom B.L., Wan C.M., Liu H.L., Wu T.X., Yu H.J., Liu Q.M., Karabatsos N., et al. Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study. Lancet 347 (1996) 1583-1586
36. Huang K.J., Yang Y.C., Lin Y.S., Huang J.H., Liu H.S., Yeh T.M., Chen S.H., Liu C.C., and Lei H.Y. The dual-specific binding of dengue virus and target cells for the antibody-dependent enhancement of dengue virus infection. J. Immunol. 176 (2006) 2825-2832
37. Kaufmann B., Nybakken G.E., Chipman P.R., Zhang W., Diamond M.S., Fremont D.H., Kuhn R.J., and Rossmann M.G. West Nile virus in complex with the Fab fragment of a neutralizing monoclonal antibody. Proc. Natl. Acad. Sci. USA 103 (2006) 12400-12404
38. Kliks S.C., Nimmanitya S., Nisalak A., and Burke D.S. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am. J. Trop. Med. Hyg. 38 (1988) 411-419
39. Kuhn R.J., Zhang W., Rossmann M.G., Pletnev S.V., Corver J., Lenches E., Jones C.T., Mukhopadhyay S., Chipman P.R., Strauss E.G., et al. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 108 (2002) 717-725
40. Kurane I., and Takasaki T. Immunogenicity and protective efficacy of the current inactivated Japanese encephalitis vaccine against different Japanese encephalitis virus strains. Vaccine 18 Suppl 2 (2000) 33-35
41. Kyle J.L., and Harris E. Global spread and persistence of Dengue. Annu. Rev. Microbiol. (2008) 10.1146/annurev.micro.62.081307.163005 Published online April 22, 2008
42. Lai C.J., Goncalvez A.P., Men R., Wernly C., Donau O., Engle R.E., and Purcell R.H. Epitope determinants of a chimpanzee dengue virus type 4 (DENV-4)-neutralizing antibody and protection against DENV-4 challenge in mice and rhesus monkeys by passively transferred humanized antibody. J. Virol. 81 (2007) 12766-12774
43. Li L., Lok S.M., Yu I.M., Zhang Y., Kuhn R.J., Chen J., and Rossmann M.G. The flavivirus precursor membrane-envelope protein complex: structure and maturation. Science 319 (2008) 1830-1834
44. Lindenbach B.D., Thiel H.J., and Rice C.M. Flaviviridae: The Viruses and Their Replication. In: Knipe D.M., and Howley P.M. (Eds). Fields Virology (2007), Lippincott-Williams & Wilkins, Philadelphia 1101-1152
45. Lok S.M., Kostyuchenko V., Nybakken G.E., Holdaway H.A., Battisti A.J., Sukupolvi-Petty S., Sedlak D., Fremont D.H., Chipman P.R., Roehrig J.T., et al. Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat. Struct. Mol. Biol. 15 (2008) 312-317
46. Mehlhop E., Whitby K., Oliphant T., Marri A., Engle M., and Diamond M.S. Complement activation is required for induction of a protective antibody response against West Nile virus infection. J. Virol. 79 (2005) 7466-7477
47. Mehlhop E., Ansarah-Sobrinho C., Johnson S., Engle M., Fremont D.H., Pierson T.C., and Diamond M.S. Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner. Cell Host Microbe 2 (2007) 417-426
48. Monath T.P. Yellow fever vaccine. Expert Rev. Vaccines 4 (2005) 553-574
49. Monath T.P. Dengue and yellow fever-challenges for the development and use of vaccines. N. Engl. J. Med. 357 (2007) 2222-2225
50. Morrey J.D., Siddharthan V., Olsen A.L., Wang H., Julander J.G., Hall J.O., Li H., Nordstrom J.L., Koenig S., Johnson S., et al. Defining limits of treatment with humanized neutralizing monoclonal antibody for West Nile virus neurological infection in a hamster model. Antimicrob. Agents Chemother. 51 (2007) 2396-2402
51. Mukhopadhyay S., Kim B.S., Chipman P.R., Rossmann M.G., and Kuhn R.J. Structure of West Nile virus. Science 302 (2003) 248
52. Mukhopadhyay S., Kuhn R.J., and Rossmann M.G. A structural perspective of the flavivirus life cycle. Nat. Rev. Microbiol. 3 (2005) 13-22
53. Nelson S., Jost C.A., Xu Q., Ess J., Martin J.E., Oliphant T., Whitehead S.S., Durbin A.P., Graham B.S., Diamond M.S., et al. Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization. PLoS Pathog. 4 (2008) e1000060
54. Nimmerjahn F., and Ravetch J.V. Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 8 (2008) 34-47
55. Nybakken G.E., Oliphant T., Johnson S., Burke S., Diamond M.S., and Fremont D.H. Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature 437 (2005) 764-769
56. Oliphant T., Engle M., Nybakken G.E., Doane C., Johnson S., Huang L., Gorlatov S., Mehlhop E., Marri A., Chung K.M., et al. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat. Med. 11 (2005) 522-530
57. Oliphant T., Nybakken G.E., Engle M., Xu Q., Nelson C.A., Sukupolvi-Petty S., Marri A., Lachmi B.E., Olshevsky U., Fremont D.H., et al. Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein. J. Virol. 80 (2006) 12149-12159
58. Oliphant T., Nybakken G.E., Austin S.K., Xu Q., Bramson J., Loeb M., Throsby M., Fremont D.H., Pierson T.C., and Diamond M.S. Induction of epitope-specific neutralizing antibodies against West Nile virus. J. Virol. 81 (2007) 11828-11839
59. Pantophlet R., and Burton D.R. Immunofocusing: antigen engineering to promote the induction of HIV-neutralizing antibodies. Trends Mol. Med. 9 (2003) 468-473
60. Pierson T.C., and Diamond M.S. Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection. Expert Rev. Mol. Med. 10 (2008) e12
61. Pierson T.C., Xu Q., Nelson S., Oliphant T., Nybakken G.E., Fremont D.H., and Diamond M.S. The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe 1 (2007) 135-145
62. Roehrig J.T. Antigenic structure of flavivirus proteins. Adv. Virus Res. 59 (2003) 141-175
63. Roehrig J.T., Bolin R.A., and Kelly R.G. Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology 246 (1998) 317-328
64. Roehrig J.T., Staudinger L.A., Hunt A.R., Mathews J.H., and Blair C.D. Antibody prophylaxis and therapy for flavivirus encephalitis infections. Ann. N Y Acad. Sci. 951 (2001) 286-297
65. Sanchez M.D., Pierson T.C., Degrace M.M., Mattei L.M., Hanna S.L., Del Piero F., and Doms R.W. The neutralizing antibody response against West Nile virus in naturally infected horses. Virology 359 (2007) 336-348
66. Schlesinger J.J., and Chapman S. Neutralizing F(ab')2 fragments of protective monoclonal antibodies to yellow fever virus (YF) envelope protein fail to protect mice against lethal YF encephalitis. J. Gen. Virol. 76 (1995) 217-220
67. Sette A., Moutaftsi M., Moyron-Quiroz J., McCausland M.M., Davies D.H., Johnston R.J., Peters B., Rafii-El-Idrissi Benhnia M., Hoffmann J., Su H.P., et al. Selective CD4+ T cell help for antibody responses to a large viral pathogen: deterministic linkage of specificities. Immunity 28 (2008) 847-858
68. Shepherd C.M., Borelli I.A., Lander G., Natarajan P., Siddavanahalli V., Bajaj C., Johnson J.E., Brooks III C.L., and Reddy V.S. VIPERdb: a relational database for structural virology. Nucleic Acids Res. 34 (2006) D386-D389
69. Stadler K., Allison S.L., Schalich J., and Heinz F.X. Proteolytic activation of tick-borne encephalitis virus by furin. J. Virol. 71 (1997) 8475-8481
70. Stiasny K., Kiermayr S., Holzmann H., and Heinz F.X. Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites. J. Virol. 80 (2006) 9557-9568
71. Stiasny K., Brandler S., Kossl C., and Heinz F.X. Probing the flavivirus membrane fusion mechanism by using monoclonal antibodies. J. Virol. 81 (2007) 11526-11531
72. Sukupolvi-Petty S., Austin S.K., Purtha W.E., Oliphant T., Nybakken G.E., Schlesinger J.J., Roehrig J.T., Gromowski G.D., Barrett A.D., Fremont D.H., et al. Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J. Virol. 81 (2007) 12816-12826
73. Throsby M., Geuijen C., Goudsmit J., Bakker A.Q., Korimbocus J., Kramer R.A., Clijsters-van der Horst M., de Jong M., Jongeneelen M., Thijsse S., et al. Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile Virus. J. Virol. 80 (2006) 6982-6992
74. Thullier P., Demangel C., Bedouelle H., Megret F., Jouan A., Deubel V., Mazie J.C., and Lafaye P. Mapping of a dengue virus neutralizing epitope critical for the infectivity of all serotypes: insight into the neutralization mechanism. J. Gen. Virol. 82 (2001) 1885-1892
75. Vaughn D.W., Green S., Kalayanarooj S., Innis B.L., Nimmannitya S., Suntayakorn S., Endy T.P., Raengsakulrach B., Rothman A.L., Ennis F.A., et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J. Infect. Dis. 181 (2000) 2-9
76. Whitehead S.S., Blaney J.E., Durbin A.P., and Murphy B.R. Prospects for a dengue virus vaccine. Nat. Rev. Microbiol. 5 (2007) 518-528
77. Xin Y.Y., Ming Z.G., Peng G.Y., Jian A., and Min L.H. Safety of a live-attenuated Japanese encephalitis virus vaccine (SA14-14-2) for children. Am. J. Trop. Med. Hyg. 39 (1988) 214-217
78. Yu I.M., Zhang W., Holdaway H.A., Li L., Kostyuchenko V.A., Chipman P.R., Kuhn R.J., Rossmann M.G., and Chen J. Structure of the immature dengue virus at low pH primes proteolytic maturation. Science 319 (2008) 1834-1837
79. Zhang Y., Corver J., Chipman P.R., Zhang W., Pletnev S.V., Sedlak D., Baker T.S., Strauss J.H., Kuhn R.J., and Rossmann M.G. Structures of immature flavivirus particles. EMBO J. 22 (2003) 2604-2613
80. Zhang Y., Kaufmann B., Chipman P.R., Kuhn R.J., and Rossmann M.G. Structure of immature West Nile virus. J. Virol. 81 (2007) 6141-6145